Skip to main content

Table 2 Bactericidal efficiency of IgY extracts

From: Production and characterization of anti-Campylobacter jejuni IgY derived from egg yolks

Strain GR1-CTL
Reduction
GR2-INO
Reduction
GR3-OMP
Reduction
GR4-BACT
Reduction
Homologous
 A2008A 17.35a (6.53) 57.57b (3.39) 50.30b (4.39) 53.20b (17.13)
 B2008A 29.57a (12.60) 95.12bc (5.50) 60.45bd (17.78) 68.20bd (8.05)
 G2008B 21.50a (14.73) 99.61bc (0.44) 48.24bd (26.87) 80.08bd (13.22)
 RM 1221 22.34a (12.52) 49.71c (20.42) 84.11bd (9.79) 64.75b (20.98)
Mean homologous 22.62a (12.41) 79.92bc (24.67) 60.03bd (21.76) 67.35b (17.21)
Heterologous
 81116 34.92 (21.48) 39.07 (22.01) 33.34 (8.97) 33.46 (16.54)
 81-176 34.92 (21.48) 39.07 (22.01) 33.34 (8.97) 33.46 (16.54)
 ATCC 700819 14.42a (5.04) 37.10b (7.76) 42.89b (33.36) 46.31b (3.08)
 ATCC 33291 6.54a (5.17) 26.30b (10.00) 31.53b (12.54) 28.76b (10.96)
Mean heterologous 20.95a (18.58) 34.86b (14.78) 35.55b (9.65) 35.79b (12.88)
  1. Mean reduction percentage of the initial count for the homologous and heterologous strains
  2. () the standard deviation for 3 biological replicates
  3. Homologous C. jejuni strains: A2008A, B2008A, G2008B, RM 1221
  4. Heterologous C. jejuni strains: 81116 and ATCC 33291
  5. On a same row a different than b and c different than d, P < 0.05, Kruskal–Wallis test followed by pairs of Mann–Whitney tests
  6. GR2-INO (orally inoculated), GR3-OMP (immunized with OMP), GR4-BACT (immunized with formalin-killed whole bacteria), GR1-CTL (control group)